Ionis Pharmaceuticals, Inc. (IONS) — Analyst outlook / Analyst consensus target is. Based on 32 analyst ratings, the consensus is bullish — 1 Strong Buy, 19 Buy, 12 Hold.
The consensus price target is $96.40 (low: $87.00, high: $103.00), representing an upside of 25.6% from the current price $76.76.
Analysts estimate Earnings Per Share (EPS) of $-3.50 and revenue of $0.62B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.04 vs est $-3.50 (beat +13.2%). 2025: actual $-2.38 vs est $-2.28 (missed -4.4%). Analyst accuracy: 90%.
IONS Stock — 12-Month Price Forecast
$96.40
▲ +25.59% Upside
Average Price Target
Based on 32 Wall Street analysts offering 12-month price targets for Ionis Pharmaceuticals, Inc., the average price target is $96.40, with a high forecast of $103.00, and a low forecast of $87.00.
The average price target represents a +25.59% change from the last price of $76.76.
Highest Price Target
$103.00
Average Price Target
$96.40
Lowest Price Target
$87.00
IONS Analyst Ratings
Buy
Based on 32 analysts giving stock ratings to Ionis Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — IONS
90%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.04
vs Est –$3.50
▲ 15.3% off
2025
Actual –$2.38
vs Est –$2.28
▼ 4.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — IONS
91%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.705B
vs Est $0.618B
▲ 12.4% off
2025
Actual $0.944B
vs Est $0.900B
▲ 4.7% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
